Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

Cervical Cancer Clinical Trial

Official title:

Clinical Performance Validation of Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05413798
• Other study ID #: IGHID12022
• Secondary ID: U54CA254564-01
• Status: Recruiting
• Phase: N/A
• Start date: May 11, 2023
• Est. completion date: August 2026

Study information

• Verified date: February 2024
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: Cheryl Hendrickson
• Phone: 919-843-2541
• Email: cheryl_hendrickson[@]med.unc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women. Cervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.

Description:

Invasive cervical cancer is a significant health burden in low and middle income countries. HIV-infected women in Africa are particularly affected and have an estimated invasive cervical cancer risk ~20-fold higher than women without HIV. Previous studies have been performed among only HIV-uninfected women or those whose HIV status was unknown. Additionally, HIV infected women are often diagnosed with invasive cervical cancer at younger ages. Cervical cancer is preventable by regular screenings which includes doing a pap smear or HPV tests. There is also treatment of precancerous cervical lesions and vaccination against high risk types of HPV. World Health Organization currently recommends high risk HPV testing for cervical cancer screening in both high and low resources settings. National Guidelines in many low and middle income countries, including South Africa, have been updated to include plans to transition from cytology or visual screening to primary HPV screening. Urine HPV testing could provide a simpler approach for cervical screening that is more easily scaled in low and middle income countries. The study hypothesizes that high-risk human papillomavirus (hrHPV) testing on urine specimens will be similar in sensitivity and specificity for the detection of cervical intra-epithelial neoplasia grade 2 or worse (CIN2+) compared to self- or clinician-collected sampling. This study will investigate whether women can collect their own samples for HPV testing using either urine or a small brush in the vagina. The results of HPV tests on urine, self-collected vaginal samples, and provider-collected cervical samples will be compared to see which sample type works best.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: August 2026
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

In order to participate in this study a subject must meet all of the eligibility criteria outlined below.

1. Confirmed HIV-1 infection

2. Age 25 years and older.

3. Be willing and able to provide written informed consent.

Exclusion Criteria:

1. Pregnant or intend to become pregnant within 90 days of enrollment

2. Have been screened for cervical cancer within the preceding year (365 days)

3. Have an active sexually transmitted infection (STI; women may participate once treated)

4. Have a surgically absent cervix

5. Have a history of cervical cancer

6. have been vaccinated against HPV.

Related Conditions & MeSH terms

• Cervical Cancer
• CIN2
• CIN3
• Uterine Cervical Neoplasms

Intervention

Other:
• Urine HPV testing
Human papillomavirus (HPV) testing in urine sample.
• Self-collected cervicovaginal specimen
Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
• Provider-collected cervical samples
Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.

Locations

Country	Name	City	State
South Africa	Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital	Westdene	Johannesburg

Sponsors (2)

Lead Sponsor	Collaborator
UNC Lineberger Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical performance of hrHPV testing in the three sample types for the detection of CIN2	The clinical performance (sensitivity, specificity, positive predictive value, and negative predictive value) for CIN2+ detection of sample collection methods namely urine, self-collected samples, and provider-collected samples will be determined.	4 weeks (Entry visit)
Secondary	Clinical performance of hrHPV testing in in the three sample types for the detection of CIN3 or worse	The clinical performance (sensitivity, specificity, positive predictive value, and negative predictive value) for CIN3+ detection or worse of sample collection methods namely urine, self-collected samples, and provider-collected samples will be determined.	4 weeks
Secondary	The proportion of participants positive for hrHPV	The high-risk human papillomavirus (hrHPV) positivity detection of urine, self-collected cervicovaginal specimen, and provider-collected cervical samples will be compared.	4 weeks

External Links

•   University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials